文献速递前列腺癌膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

液体活检在泌尿生殖系统恶性肿瘤管理中的作用

The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies.
PubMed 文献 · Eur Urol · 2025-08-18

该研究系统综述了2015至2025年间FDA批准,识别出9项与泌尿生殖系统癌症相关且需分子检测的药物批准,液体活检目前主要用于预测治疗反应,可用于为多数此类适应症筛选患者,作者鼓励临床医生在指征明确时常规使用以改善生物标志物筛选患者的结局。

要点

  • 液体活检当前基于监管批准的用途是预测治疗反应。
  • 有9项FDA批准的药物或药物组合适用于泌尿生殖系统恶性肿瘤患者的临床实践。
  • 液体活检目前可用于为多数上述适应症识别患者。

核心结论

  • 液体活检在常规临床实践中已有多个临床适应症,FDA批准的适应症可显著改善生物标志物筛选患者的结局。
  • 鼓励所有治疗泌尿生殖系统恶性肿瘤患者的医生在指征明确时常规使用这些工具以改善患者护理。
  • 预计未来将有更多应用可用于常规临床使用。

研究设计与样本

  • 系统综述2015年至2025年间所有FDA批准,检索多个FDA数据库以捕获肿瘤特异性和组织不可知性批准。
  • 共识别1119项批准,其中9项与泌尿生殖系统癌症相关且需要分子检测的独特药物批准。
  • 通过PubMed识别用于这些批准的注册试验并呈现结果;对于次要终点,识别过去10年内发表的示例。

主要发现

  • 液体活检测试基于监管批准的当前用途是预测治疗反应。
  • 有9项FDA批准的药物或药物组合适用于泌尿生殖系统恶性肿瘤患者的临床实践。
  • 液体活检测试目前可用于为多数这些适应症识别患者。
  • 突出了当前液体活检测试相关的局限性。

临床怎么用

  • 所有治疗泌尿生殖系统恶性肿瘤患者的医生被鼓励在指征明确时常规使用这些工具以改善患者护理。

局限性

  • 突出了当前液体活检测试相关的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Liquid biopsy testing refers to the use of specific analytical methods to detect disease-related biomarkers in blood or its components. These tests can be either qualitative or quantitative. Liquid biopsy testing is increasingly used in patient care. Here, we explore all the current Food and Drug Administration (FDA)-approved indications for liquid biopsies related to genitourinary oncology. The secondary objective is to describe a few other potential uses of this technology that may become approved soon. METHODS: We conducted a systematic review of all FDA approvals from 2015 through 2025. We interrogated multiple FDA databases to capture both tumor-specific and tissue-agnostic approvals. We limited the search to indications related to or requiring biomarker testing to assess the value of liquid biopsy testing. A total of 1119 approvals were identified. Of these, nine unique drug approvals related to genitourinary cancers require molecular testing. We then identified the registrational trials used for those approvals through PubMed and present the results here. For the secondary endpoints, we identified examples published within the past 10 yr. KEY FINDINGS AND LIMITATIONS: The current use for liquid biopsy testing based on regulatory approval is for predicting treatment response. There are nine FDA-approved drugs or drug combinations applicable to clinical practice for patients with genitourinary malignancies. Liquid biopsy testing is currently available to identify patients for most of these indications. We highlight the limitations associated with current liquid biopsy testing. CONCLUSIONS AND CLINICAL IMPLICATIONS: Currently, there are multiple clinical indications for liquid biopsy in routine clinical practice. These FDA-approved indications can significantly improve the outcomes for biomarker-selected patients. All providers treating patients with a genitourinary malignancy are encouraged to use these tools regularly when indicated to improve patient care. Additional applications are expected to become available for routine clinical use in the future.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Maughan BL, Dyrskjøt L, Grivas P, et al. The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies. Eur Urol. 2025. PMID: 40829964. doi:10.1016/j.eururo.2025.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。